Abels R I
R. W. Johnson Pharmaceutical Research Institute, Raritan, N.J.
Acta Haematol. 1992;87 Suppl 1:4-11. doi: 10.1159/000204780.
Advanced cancer is often accompanied by anaemia, which may worsen with concomitant administration of chemotherapy. Serum erythropoietin (EPO) concentrations are lower in cancer patients than in patients with iron deficiency, suggesting that the anaemia observed in cancer patients is at least partially due to a relative deficiency of EPO. Consequently, we studied the effects of recombinant human erythropoietin (r-HuEPO) therapy in three populations of anaemic cancer patients: patients not receiving concomitant chemotherapy or radiotherapy; patients receiving cyclic, non-cisplatin-containing chemotherapy, and patients receiving cyclic cisplatin-containing chemotherapy. Therapy with r-HuEPO was well tolerated; it increased haematocrit levels and corrected anaemia, irrespective of concomitant chemotherapy or the type of chemotherapy administered. A dose of 150 U/kg r-HuEPO given subcutaneously 3 times weekly decreased transfusion requirements after the 1st month of therapy; improved functional capacity was noted in patients who achieved a significant increase in haematocrit in response to r-HuEPO therapy.
晚期癌症常伴有贫血，化疗同时进行时贫血可能会加重。癌症患者血清促红细胞生成素（EPO）浓度低于缺铁性贫血患者，这表明癌症患者中观察到的贫血至少部分归因于EPO相对缺乏。因此，我们研究了重组人促红细胞生成素（r-HuEPO）治疗对三组贫血癌症患者的效果：未同时接受化疗或放疗的患者；接受不含顺铂的周期性化疗的患者；接受含顺铂的周期性化疗的患者。r-HuEPO治疗耐受性良好；无论是否同时进行化疗或所给予的化疗类型如何，它都能提高血细胞比容水平并纠正贫血。每周皮下注射3次150 U/kg的r-HuEPO剂量，在治疗第1个月后可减少输血需求；对r-HuEPO治疗有反应且血细胞比容显著增加的患者，其功能能力有所改善。
